Sunitiba Malate is an antineoplastic agent and a potent RTK inhibitor which includes Flk-1 (VEGFR2) as a primary target. It also is a potent, ATP-competitive inhibitor of VEGFR, PDGFR-β and c-Kit (KIT). Sunitiba Malate inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models. Sunitinib Malate is an inhibitor of c-Fms-CSF-1R, Flt-1, Flt-3/Flk-2, Flt-4, PDGFR-α and Ret.
Sun, L., et al.: J. Med. Chem., 46, 1116 (2003), Mendel, D.B., et al.: Clin. Cancer Res., 9, 327 (2003), Sistla, A., et al.: Drug Dev. Ind. Pharm., 30, 19 (2004), Sakamoto, K.M., et al.: Curr. Opin. Invest. Drugs, 5. 1329 (2004),
See how others have used Sunitinib Malate (CAS 341031-54-7). Click on the entry to view the PubMed entry .
PMID: # 25002903 Chen, J. et al. 2014. Evidence-based complementary and alternative medicine : eCAM. 2014: 484269.
PMID: # 23781255 Ho, JY. et al. 2013. Evid Based Complement Alternat Med. 2013: 161628.
PMID: # 22791880 2012. Clin. Cancer Res. 18: 4549-59.
PMID: # 23047550 2012. Br. J. Cancer. 107: 1702-13.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.